HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer.

AbstractBACKGROUND:
We conducted a study of patients who underwent anatomic resection with adjuvant chemotherapy to determine if thoracoscopic lobectomy enables more effective administration of adjuvant chemotherapy than lobectomy by thoracotomy.
METHODS:
We reviewed the outcomes of 100 consecutive patients with non-small cell lung cancer (NSCLC) who underwent lobectomy and received adjuvant chemotherapy (1999 to 2004). The variables analyzed were time to initiation of chemotherapy, percentage of planned regimen received, number of delayed or reduced chemotherapy doses, toxicity grade, length of hospitalization, chest tube duration, 30-day mortality, and major complications (pneumonia, respiratory failure, atrial fibrillation). The chi2 test and Student t test were used to compare dichotomous and continuous variables, respectively.
RESULTS:
Complete resection was performed by thoracotomy in 43 patients and by thoracoscopy in 57 (no conversions). All patients received adjuvant chemotherapy, and 20 (20%) received adjuvant radiation therapy: 13 (30%) of 43 in the thoracotomy group and 7 (12%) of 57 in the thoracoscopy group (p = 0.04). Patients undergoing thoracoscopic lobectomy had significantly fewer delayed (18% versus 58%, p < 0.001) and reduced (26% versus 49%, p = 0.02) chemotherapy doses. A higher percentage of patients undergoing thoracoscopic resection received 75% or more of their planned adjuvant regimen without delayed or reduced doses (61% versus 40%, p = 0.03). There were no significant differences in time to initiation of chemotherapy or toxicity. Patients undergoing a thoracoscopic lobectomy had a shorter median length of hospitalization (4 days versus 5 days, p = 0.02).
CONCLUSIONS:
Thoracoscopy was associated with an overall higher compliance rate and fewer delayed or reduced doses of chemotherapy in patients receiving adjuvant chemotherapy.
AuthorsRebecca P Petersen, DuyKhanh Pham, William R Burfeind, Steven I Hanish, Eric M Toloza, David H Harpole Jr, Thomas A D'Amico
JournalThe Annals of thoracic surgery (Ann Thorac Surg) Vol. 83 Issue 4 Pg. 1245-9; discussion 1250 (Apr 2007) ISSN: 1552-6259 [Electronic] Netherlands
PMID17383320 (Publication Type: Journal Article)
Topics
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
  • Biopsy, Needle
  • Carcinoma, Non-Small-Cell Lung (mortality, pathology, therapy)
  • Chemotherapy, Adjuvant
  • Cohort Studies
  • Female
  • Humans
  • Lung Neoplasms (mortality, pathology, therapy)
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Patient Compliance (statistics & numerical data)
  • Pneumonectomy (adverse effects, methods)
  • Probability
  • Prognosis
  • Retrospective Studies
  • Risk Assessment
  • Statistics, Nonparametric
  • Survival Analysis
  • Thoracoscopy (adverse effects, methods)
  • Thoracotomy (adverse effects, methods)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: